vs
固瑞克（GGG）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是固瑞克的1.0倍（$622.0M vs $593.2M），Royalty Pharma plc净利率更高（34.4% vs 22.3%，领先12.1%），固瑞克同比增速更快（8.1% vs 4.8%），过去两年固瑞克的营收复合增速更高（9.8% vs 4.6%）
固瑞克（Graco Inc.）是总部位于美国明尼苏达州明尼阿波利斯的工业企业，专注于流体处理系统及相关产品的研发与制造，旗下产品销往全球各地，广泛应用于多个工业领域。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
GGG vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$593.2M
营收增速更快
GGG
高出3.3%
4.8%
净利率更高
RPRX
高出12.1%
22.3%
两年增速更快
GGG
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $593.2M | $622.0M |
| 净利润 | $132.5M | $214.2M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 26.7% | 62.4% |
| 净利率 | 22.3% | 34.4% |
| 营收同比 | 8.1% | 4.8% |
| 净利润同比 | 21.9% | 2.9% |
| 每股收益（稀释后） | $0.78 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GGGRPRX
| Q4 25 | $593.2M | $622.0M | ||
| Q3 25 | $543.4M | $609.3M | ||
| Q2 25 | $571.8M | $578.7M | ||
| Q1 25 | $528.3M | $568.2M | ||
| Q4 24 | $548.7M | $593.6M | ||
| Q3 24 | $519.2M | $564.7M | ||
| Q2 24 | $553.2M | $537.3M | ||
| Q1 24 | $492.2M | $568.0M |
净利润GGGRPRX
| Q4 25 | $132.5M | $214.2M | ||
| Q3 25 | $137.6M | $288.2M | ||
| Q2 25 | $127.6M | $30.2M | ||
| Q1 25 | $124.1M | $238.3M | ||
| Q4 24 | $108.7M | $208.2M | ||
| Q3 24 | $122.2M | $544.0M | ||
| Q2 24 | $133.0M | $102.0M | ||
| Q1 24 | $122.2M | $4.8M |
毛利率GGGRPRX
| Q4 25 | 51.7% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 52.4% | — | ||
| Q1 25 | 52.6% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 53.2% | — | ||
| Q2 24 | 54.4% | — | ||
| Q1 24 | 54.1% | — |
营业利润率GGGRPRX
| Q4 25 | 26.7% | 62.4% | ||
| Q3 25 | 30.3% | 70.1% | ||
| Q2 25 | 27.5% | 36.3% | ||
| Q1 25 | 27.3% | 94.0% | ||
| Q4 24 | 23.7% | 60.9% | ||
| Q3 24 | 28.1% | — | ||
| Q2 24 | 29.2% | 50.2% | ||
| Q1 24 | 27.0% | -13.0% |
净利率GGGRPRX
| Q4 25 | 22.3% | 34.4% | ||
| Q3 25 | 25.3% | 47.3% | ||
| Q2 25 | 22.3% | 5.2% | ||
| Q1 25 | 23.5% | 41.9% | ||
| Q4 24 | 19.8% | 35.1% | ||
| Q3 24 | 23.5% | 96.3% | ||
| Q2 24 | 24.0% | 19.0% | ||
| Q1 24 | 24.8% | 0.8% |
每股收益（稀释后）GGGRPRX
| Q4 25 | $0.78 | $0.49 | ||
| Q3 25 | $0.82 | $0.67 | ||
| Q2 25 | $0.76 | $0.07 | ||
| Q1 25 | $0.72 | $0.55 | ||
| Q4 24 | $0.63 | $0.46 | ||
| Q3 24 | $0.71 | $1.21 | ||
| Q2 24 | $0.77 | $0.23 | ||
| Q1 24 | $0.71 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $624.1M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $3.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资GGGRPRX
| Q4 25 | $624.1M | $618.7M | ||
| Q3 25 | $618.7M | $938.9M | ||
| Q2 25 | $534.9M | $631.9M | ||
| Q1 25 | $536.1M | $1.1B | ||
| Q4 24 | $675.3M | $929.0M | ||
| Q3 24 | $764.5M | $950.1M | ||
| Q2 24 | $666.0M | $1.8B | ||
| Q1 24 | $622.7M | $843.0M |
总债务GGGRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益GGGRPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.5B | $9.5B | ||
| Q1 25 | $2.5B | $9.8B | ||
| Q4 24 | $2.6B | $10.3B | ||
| Q3 24 | $2.5B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.3B | $9.9B |
总资产GGGRPRX
| Q4 25 | $3.3B | $19.6B | ||
| Q3 25 | $3.2B | $19.3B | ||
| Q2 25 | $3.0B | $18.3B | ||
| Q1 25 | $3.0B | $17.6B | ||
| Q4 24 | $3.1B | $18.2B | ||
| Q3 24 | $3.0B | $18.0B | ||
| Q2 24 | $2.9B | $17.7B | ||
| Q1 24 | $2.8B | $16.1B |
负债/权益比GGGRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $196.3M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $184.3M | — |
| 自由现金流率自由现金流/营收 | 31.1% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 1.48× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $637.9M | — |
8季度趋势，按日历期对齐
经营现金流GGGRPRX
| Q4 25 | $196.3M | $827.1M | ||
| Q3 25 | $179.2M | $702.6M | ||
| Q2 25 | $182.7M | $364.0M | ||
| Q1 25 | $125.4M | $596.1M | ||
| Q4 24 | $185.2M | $742.5M | ||
| Q3 24 | $178.6M | $703.6M | ||
| Q2 24 | $139.0M | $658.2M | ||
| Q1 24 | $118.9M | $664.6M |
自由现金流GGGRPRX
| Q4 25 | $184.3M | — | ||
| Q3 25 | $175.7M | — | ||
| Q2 25 | $163.1M | — | ||
| Q1 25 | $114.8M | — | ||
| Q4 24 | $171.3M | — | ||
| Q3 24 | $159.2M | — | ||
| Q2 24 | $102.7M | — | ||
| Q1 24 | $81.7M | — |
自由现金流率GGGRPRX
| Q4 25 | 31.1% | — | ||
| Q3 25 | 32.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 21.7% | — | ||
| Q4 24 | 31.2% | — | ||
| Q3 24 | 30.7% | — | ||
| Q2 24 | 18.6% | — | ||
| Q1 24 | 16.6% | — |
资本支出强度GGGRPRX
| Q4 25 | 2.0% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 7.6% | — |
现金转化率GGGRPRX
| Q4 25 | 1.48× | 3.86× | ||
| Q3 25 | 1.30× | 2.44× | ||
| Q2 25 | 1.43× | 12.06× | ||
| Q1 25 | 1.01× | 2.50× | ||
| Q4 24 | 1.70× | 3.57× | ||
| Q3 24 | 1.46× | 1.29× | ||
| Q2 24 | 1.05× | 6.45× | ||
| Q1 24 | 0.97× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GGG
| Industrial | $284.3M | 48% |
| Contractor | $265.5M | 45% |
| Other | $43.4M | 7% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
